DBI and Alzheimer disease: ACBP has been reported to be increased in the cerebrospinal fluid (CSF) of AD patients, and inhibition of ACBP may increase autophagic flux and thus clearance of misfolded proteins.[41] Thus, targeting ACBP in excitatory neurons could represent a novel approach to AD therapeutics.